Digital
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
Digitalization is expected to reform the European pharmaceutical industry. But it will also change perceptions towards technology and current regulatory skillsets.
FDA final rule effective date is March 7, 2033, when it will assign new 12-digit NDCs and convert all previously assigned 10-digit NDCs for OTC and Rx drugs to the 12-digit NDC format and start a three-year clock for compliance through March 6, 2036.
India pharma leaders emphasize the need for AI integration beyond pilots, calling for an enterprise mindset to drive AI adoption and a focus on re-skilling for ‘everyone’. Discussions touched on AI’s role in driving manufacturing efficiencies and also India’s innovation trajectory.
Sanofi’s EVP Madeleine Roach details ways in which snackable, generative and expert AI are transforming innovation, helping halve the time for a drug to move from discovery to market. AI has aided a cut in mRNA design time by 50% at the "first AI-powered biopharma at scale."
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
Google DeepMind’s vice-president, Science and Strategic Initiatives, talks about the potential of the group’s new generation of AI models designed to address problems across biology, heralding a new era of science and medical advances.
The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.
MSD’s Chief AI Officer talks about how AI is reshaping R&D, enabling the company to double its molecules in discovery, foundational models and leading 'differently' in the age of AI.
Bristol Myers Squibb will deploy Evinova's AI-native platform across its global clinical portfolio to optimize trial design, reduce costs, and accelerate development timelines.
“We remain fully committed to the integrated growth strategy that has enabled us to deliver significant growth and value creation, over the better part of the past decade,” says CEO Shailesh Jejurikar as firm reports net sales up 1% in latest quarter.
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.